Abstract 5784
Background
About 20-30% patients with newly diagnosed multiple myeloma (ND MM) experience damage to kidneys and in 2-4% of cases, hemodialysis is required. NT‐proBNP synthesize in atria and ventricles cardiomyocytes and excreted by the kidney. The purpose of this work was to analyze the predictive utility of NT-proBNP in patients with ND MM, complicated by severe dialysis-dependent renal failure (RF).
Methods
Between 10.2016 and 07.2017, 20 patients with ND MM and terminal RF enrolled in this prospective study. Exclusion criteria were diagnosed at AL-amyloidosis and a significant cardiac pathology. Samples for NT‐proBNP analysis were collected before antimyeloma chemotherapy and not earlier than 36 hours after hemodialysis. The ROC analysis determined the area under the error curve as 0.75 (0.52-0.97), and the cut-off point for the OS was an NT-proBNP concentration of 7036 pg/ml (sensitivity 79%; specificity 44%). According to these data, the patients were divided into two groups, depending on the NT-proBNP value less than (n = 9) or more than (n = 11) 7000 pg/ml for the subsequent analysis.
Results
The median age of the patients was 67 years (range, 63-76). Median of estimated glomerular filtration CKD-EPI rate was 4.0 (IQR 4.0-5.0) ml/min/1.73 m2. The only difference between the groups was the volume of residual diuresis 1250 (550-2500) vs. 50.0 (37.5-1038) ml/day (P = 0.036). As induction therapies, 11 (55%) patients underwent a VCD regimen, 7 (35%) - VD), and 2 (10%) - VMP. The ASCT accomplished in 1 patient. The renal response was documented in 4 (25.0%) cases including one complete response. With a median follow-up of 17.3 months, the overall OS was 48.5±11.5%. The 18-month OS for comparison groups were 76.6±14.8% and 27.3±13.4% (P = 0.020), respectively. There were no causes of death due to cardiovascular complications.
Conclusions
According to our data, NT-proBNP > 7400 pg/ml are associated with the severity of kidney damage and the risk of non-cardiac mortality in ND MM patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5995 - Invasive fungal diseases caused by rare pathogens in patients after hematopoietic stem cell transplantation (HSCT) & chemotherapy
Presenter: Yuliya Rogacheva
Session: Poster Display session 1
Resources:
Abstract
2961 - Safety and pharmacokinetics of novel CXCR4 antagonist YF-H-2015005 in the mobilization of hematopoietic stem cells in patients with non-Hodgkin's lymphoma
Presenter: Weiping Liu
Session: Poster Display session 1
Resources:
Abstract
5771 - Chemotherapy associated Hyponatremia in Hematological Malignancies: A retrospective study of 189 patients treated in a single medical center
Presenter: Vadim Lesan
Session: Poster Display session 1
Resources:
Abstract
1165 - Risk factors for Bacteremia-Associated Mortality of Aeromona sobria in Hematologic Malignancies
Presenter: Gabriel De la Cruz-Kú
Session: Poster Display session 1
Resources:
Abstract
5287 - Use of droplet digital polymerase chain reaction for detecting minimal residual disease: a prospective, multi-institutional study
Presenter: Hyunkyung Park
Session: Poster Display session 1
Resources:
Abstract
1886 - RUBIH2 — Use of NGS in haematological malignancies: from real world data to national recommendations, an innovative program to evaluate the impact of healthcare technology on patient care
Presenter: Severine Coquerelle
Session: Poster Display session 1
Resources:
Abstract
1940 - Outcomes of chronic myeloid leukemia with T315I mutation in the absence of targeted therapy or hematopoietic stem cell transplantation
Presenter: Nageswara Palukuri
Session: Poster Display session 1
Resources:
Abstract
1946 - Is bone marrow examination indispensible in chronic myeloid Leukemia at diagnosis ?
Presenter: Nageswara Palukuri
Session: Poster Display session 1
Resources:
Abstract
1904 - Incidence of Imatinib Resistance in Chronic Myeloid Leukemia (CML) Patients: Experience from Resource Poor Centre of Eastern India
Presenter: Debmalya Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract
3245 - BCR-ABL transcript variant’s significance in chronic myeloid leukemia in chronic phase: Institutional experience from a developing country
Presenter: Siva Prasad
Session: Poster Display session 1
Resources:
Abstract